Ignite Creation Date:
2024-05-06 @ 2:52 PM
Last Modification Date:
2024-10-26 @ 1:39 PM
Study NCT ID:
NCT04459663
Status:
UNKNOWN
Last Update Posted:
2020-07-07
First Post:
2020-06-27
Brief Title:
JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy
Sponsor:
Li Zhang MD
Organization:
Sun Yat-sen University
Study Overview
Official Title:
A Single-arm Single-center Phase II Clinical Study to Investigate the Efficacy and Safety of JS001 Combined With Axitinib in the Treatment of Advanced Non-small Cell Lung Cancer NSCLC With Negative Driving Gene After First-line Chemotherapy
Status:
UNKNOWN
Status Verified Date:
2020-07
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase II open single-center clinical study to evaluate the efficacy and safety of JS001 combined with Axitinib in the treatment of advanced non-small cell lung cancer without activated EGFR mutation ALK fusion and ROS fusion after or during first-line chemotherapy About 50 subjects will be included in this study and will be treated with JS001 combined with acitinib Each cycle is 21 days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None